These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 14724976)

  • 21. [Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology].
    Brandts B; Van Bracht M; Dirkmann D; Borchard R; Wickenbrock I; Prull MW; Meine M; Trappe HJ
    Med Klin (Munich); 2004 Jul; 99(7):341-6. PubMed ID: 15322712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Class III effects of dofetilide and arrhythmias are modulated by [K+]o in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.
    Ducroq J; Rouet R; Sallé L; Puddu PE; Repessé Y; Ghadanfar M; Ducouret P; Gérard JL
    Eur J Pharmacol; 2006 Feb; 532(3):279-89. PubMed ID: 16480976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The research practice of anti-arrhythmic agents targeting on potassium ion channel].
    Yang Q; Wang XJ; Tang YQ; You QD
    Yao Xue Xue Bao; 2011 Jan; 46(1):12-8. PubMed ID: 21465803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pure class III antiarrhythmic drugs: focus on dofetilide.
    Doshi SK; Singh BN
    J Cardiovasc Pharmacol Ther; 2000 Oct; 5(4):237-47. PubMed ID: 11150393
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacist's corner. Part I: Antiarrhythmic agents use in the surgical patient.
    Donnelly AJ
    AORN J; 1991 May; 53(5):1261-6. PubMed ID: 2059024
    [No Abstract]   [Full Text] [Related]  

  • 26. Potential antiarrhythmic agents. 3. 4-amino-N-(2-(substituted amino)ethyl)-2,6-dimethylbenzamides.
    Yung DK; Lo EK; Vohra MM
    J Pharm Sci; 1972 Dec; 61(12):1953-9. PubMed ID: 4638102
    [No Abstract]   [Full Text] [Related]  

  • 27. Safe and effective pharmacologic management of arrhythmias.
    Razavi M
    Tex Heart Inst J; 2005; 32(2):209-11. PubMed ID: 16107117
    [No Abstract]   [Full Text] [Related]  

  • 28. The clinical pharmacology of lidocaine as an antiarrhythmic drug.
    West J Med; 1976 Jan; 124(1):36-43. PubMed ID: 1251605
    [No Abstract]   [Full Text] [Related]  

  • 29. Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
    Lumma WC; Wohl RA; Davey DD; Argentieri TM; DeVita RJ; Gomez RP; Jain VK; Marisca AJ; Morgan TK; Reiser HJ
    J Med Chem; 1987 May; 30(5):755-8. PubMed ID: 3572962
    [No Abstract]   [Full Text] [Related]  

  • 30. Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.
    Piatnitski Chekler EL; Butera JA; Di L; Swillo RE; Morgan GA; Rossman EI; Huselton C; Larsen BD; Hennan JK
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4551-4. PubMed ID: 19616941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.
    Pedersen HS; Elming H; Seibaek M; Burchardt H; Brendorp B; Torp-Pedersen C; Køber L;
    Am J Cardiol; 2007 Sep; 100(5):876-80. PubMed ID: 17719337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical differences between the newer antiarrhythmic agents.
    Camm AJ
    Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Search for new drugs with antiarrhythmic properties among derivatives of adamant-2-ylamides of alkylamidocarbonic acids].
    Turilova AI; Avdiutina NI; Piatin BM; Grushevskaia LN; Gan'shina TS; Mirzoian RS
    Eksp Klin Farmakol; 2013; 76(8):20-3. PubMed ID: 24228484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DIAMOND antiarrhythmic trials. Danish Investigations of Arrhythmia and Mortality on Dofetilide.
    Møller M
    Lancet; 1996 Dec; 348(9041):1597-8. PubMed ID: 8950921
    [No Abstract]   [Full Text] [Related]  

  • 35. [Heart failure and sudden cardiac death: pharmacological and nonpharmacological treatment possibilities from the viewpoint of the rhythmologist].
    Schmitt C
    Z Kardiol; 2000; 89 Suppl 7():55-9. PubMed ID: 11098560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells.
    Gwilt M; Arrowsmith JE; Blackburn KJ; Burges RA; Cross PE; Dalrymple HW; Higgins AJ
    J Pharmacol Exp Ther; 1991 Jan; 256(1):318-24. PubMed ID: 1988662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
    Yamamoto W; Hashimoto N; Matsuura J; Machida T; Ogino Y; Kobayashi T; Yamanaka Y; Ishiwata N; Yamashita T; Tanimoto K; Miyoshi S; Fukuda K; Nakaya H; Ogawa S
    J Cardiovasc Pharmacol; 2014 May; 63(5):421-7. PubMed ID: 24805146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further observations on the experimental antidysrhythmic activity of indoramin hydrochloride.
    Rashid S; Alps BJ
    J Pharm Pharmacol; 1973 Sep; 25(9):700-4. PubMed ID: 4148504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.